Autonomix Medical, Inc. (NASDAQ:AMIX) Stock Short Interest Report for October

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 58,986 shares, a growth of 119.9% from the September 30th total of 26,830 shares. Currently, 6.4% of the shares of the company are short sold. Based on an average daily volume of 282,590 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

AMIX has been the topic of a number of recent research reports. Wall Street Zen upgraded Autonomix Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $42.00.

Autonomix Medical Trading Up 2.5%

NASDAQ:AMIX traded up $0.05 during trading hours on Friday, reaching $2.09. 11,002 shares of the company were exchanged, compared to its average volume of 1,407,755. The stock’s 50-day moving average is $3.89 and its 200-day moving average is $6.86. Autonomix Medical has a twelve month low of $2.04 and a twelve month high of $32.55. The firm has a market cap of $2.03 million, a PE ratio of -0.05 and a beta of -0.96.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. As a group, research analysts anticipate that Autonomix Medical will post -20.17 EPS for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.